Oculis Secures Full Rights to Privosegtor and ACT-02 in $3.8 Million Deal with Accure

Oculis Holding AG (Nasdaq: OCS) announced on 8 August 2026 that it will acquire Accure Therapeutics’ rights to the neu...

Read story →